SEC Filing Summary: Renovaro Biosciences Inc. (RENB)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Renovaro Biosciences Inc. on February 7, 2024, covering events occurring on February 1, 2024. The company is a Delaware corporation with its principal executive offices in Los Angeles, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "RENB."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than financial performance.
Material Changes
On February 1, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, effective immediately. This amendment was approved by stockholders at a special meeting held on January 25, 2024. The key changes include:
- Increase in total authorized capital stock from 110,000,000 to 360,000,000 shares.
- Increase in authorized common stock (par value $0.0001 per share) from 100,000,000 to 350,000,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the execution of the share authorization amendment.
Investor Verification Checklist
- Verify the exact number of authorized shares increased to 350,000,000 for common stock.
- Confirm the effective date of the amendment was February 1, 2024.
- Review the full text of the Certificate of Amendment attached as Exhibit 3.1 for any additional terms.
- Note that this filing does not indicate any immediate issuance of new shares, only an increase in authorization.